You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 7, 2025

Indocyanine green - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for indocyanine green and what is the scope of patent protection?

Indocyanine green is the generic ingredient in three branded drugs marketed by Renew Pharms and Novadaq Tech, and is included in three NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Indocyanine green has fifty-five patent family members in eleven countries.

There are three drug master file entries for indocyanine green. Three suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for indocyanine green
Recent Clinical Trials for indocyanine green

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Alabama at BirminghamPhase 4
Stryker NordicPhase 4
Northwestern UniversityPhase 4

See all indocyanine green clinical trials

Generic filers with tentative approvals for INDOCYANINE GREEN
Applicant Application No. Strength Dosage Form
⤷  Try for Free⤷  Try for Free40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE;INJECTION
⤷  Try for Free⤷  Try for Free10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE;INJECTION
⤷  Try for Free⤷  Try for Free50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Medical Subject Heading (MeSH) Categories for indocyanine green
Anatomical Therapeutic Chemical (ATC) Classes for indocyanine green
Paragraph IV (Patent) Challenges for INDOCYANINE GREEN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SPY AGENT GREEN KIT For Injection indocyanine green 25 mg/vial 211580 1 2022-11-28

US Patents and Regulatory Information for indocyanine green

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novadaq Tech SPY AGENT GREEN KIT indocyanine green POWDER;INTRAVENOUS, INTERSTITIAL 211580-001 Nov 21, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Renew Pharms IC-GREEN indocyanine green INJECTABLE;INJECTION 011525-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Novadaq Tech SPY AGENT GREEN KIT indocyanine green POWDER;INTRAVENOUS, INTERSTITIAL 211580-001 Nov 21, 2018 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Renew Pharms INDOCYANINE GREEN indocyanine green INJECTABLE;INJECTION 040811-001 Nov 21, 2007 AP RX No Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for indocyanine green

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novadaq Tech SPY AGENT GREEN KIT indocyanine green POWDER;INTRAVENOUS, INTERSTITIAL 211580-001 Nov 21, 2018 ⤷  Try for Free ⤷  Try for Free
Novadaq Tech SPY AGENT GREEN KIT indocyanine green POWDER;INTRAVENOUS, INTERSTITIAL 211580-001 Nov 21, 2018 ⤷  Try for Free ⤷  Try for Free
Novadaq Tech SPY AGENT GREEN KIT indocyanine green POWDER;INTRAVENOUS, INTERSTITIAL 211580-001 Nov 21, 2018 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for indocyanine green

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2009092162 ⤷  Try for Free
South Korea 102012880 ⤷  Try for Free
Japan 2016135253 組織灌流を評価するための方法及びシステム (METHOD AND SYSTEM FOR EVALUATING TISSUE PERFUSION) ⤷  Try for Free
Canada 2963450 QUANTIFICATION DE CIRCULATION SANGUINE ABSOLUE DANS UN TISSU A L'AIDE DE PHOTOPLETHYSMOGRAPHIE INDUITE PAR FLUORESCENCE (QUANTIFICATION OF ABSOLUTE BLOOD FLOW IN TISSUE USING FLUORESCENCE-MEDIATED PHOTOPLETHYSMOGRAPHY) ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Market Dynamics and Financial Trajectory for Indocyanine Green

Last updated: July 4, 2025

Introduction

Indocyanine Green (ICG), a near-infrared fluorescent dye, has emerged as a critical tool in modern medicine, particularly for diagnostic imaging and surgical procedures. Used primarily in ophthalmology, cardiology, and liver function assessments, ICG's market potential hinges on its ability to enhance real-time visualization during minimally invasive surgeries. As healthcare systems prioritize precision medicine, understanding ICG's market dynamics and financial outlook equips business professionals with actionable insights to navigate this niche yet growing segment of the pharmaceutical industry.

Overview of Indocyanine Green

ICG, first approved by the FDA in 1959, functions as a tracer dye that binds to plasma proteins and fluoresces under specific light wavelengths. This property makes it indispensable for applications like retinal angiography and hepatic function testing. Major manufacturers, including Akorn Pharmaceuticals and Novartis, dominate production, with global sales driven by increasing demand for advanced imaging technologies. In 2023, ICG's market penetration expanded due to its integration into robotic-assisted surgeries, such as those performed with da Vinci systems, where it improves tissue perfusion assessment.

The drug's stability and rapid clearance from the body minimize side effects, positioning it as a safer alternative to traditional contrast agents. However, its market relies on stringent quality controls and regulatory compliance, with patents protecting formulations and delivery methods. For instance, key patents held by original developers have extended exclusivity, shielding revenues until recent expirations opened doors for generics.

Current Market Dynamics

ICG's market is experiencing steady growth, fueled by technological advancements and rising surgical volumes. In 2022, the global ICG market reached an estimated value of $150 million, according to industry reports, with a compound annual growth rate (CAGR) of 7.5% projected through 2030. This expansion stems from increasing adoption in emerging markets like Asia-Pacific, where countries such as China and India are investing in healthcare infrastructure to support aging populations and chronic disease management.

Key drivers include the surge in minimally invasive procedures, which accounted for over 60% of ICG's applications in 2023. For example, in ophthalmology, ICG angiography helps detect retinal disorders, boosting demand amid rising diabetes-related eye conditions. Competition intensifies from alternatives like fluorescein sodium, but ICG's superior safety profile and real-time imaging capabilities maintain its edge. Major players like Akorn and Guerbet dominate, holding approximately 45% of the market share through strategic partnerships and expanded distribution networks.

Regulatory factors play a pivotal role, with the FDA and EMA enforcing strict guidelines on ICG's purity and sterility. Recent approvals, such as expanded use in fluorescence-guided surgery, have unlocked new revenue streams. However, supply chain disruptions, highlighted during the COVID-19 pandemic, exposed vulnerabilities, leading to price fluctuations—ICG costs averaged $200 per vial in 2023, up 15% from 2021 due to raw material shortages.

Geographically, North America leads with a 40% market share, driven by high healthcare spending and innovation hubs like the U.S. Conversely, Europe faces pricing pressures from government reimbursements, while Asia-Pacific offers untapped potential, with growth rates exceeding 10% annually. Barriers include patent expirations, which could erode premiums as generics from companies like Sandoz enter the fray, potentially capping prices at 20-30% below branded versions.

Financial Trajectory and Projections

Financially, ICG has demonstrated resilience, with global revenues climbing from $120 million in 2018 to $150 million in 2023. Akorn Pharmaceuticals, a primary supplier, reported ICG-related earnings growth of 8% year-over-year in its latest fiscal reports, attributed to volume increases in surgical applications. Profit margins remain robust at 25-30%, bolstered by low manufacturing costs and high demand in premium healthcare settings.

Looking ahead, analysts forecast revenues to hit $220 million by 2028, propelled by a 6-8% CAGR. This trajectory hinges on R&D investments, such as novel formulations for broader applications in oncology and neurology. For instance, ongoing trials exploring ICG in tumor margin identification could add $50 million in annual sales if approved. Financial metrics underscore stability: return on investment (ROI) for ICG-focused ventures averages 15%, outpacing the broader pharmaceutical sector's 12%.

Challenges loom, including economic headwinds that may suppress elective procedures, potentially delaying growth. Currency fluctuations also impact exporters, with the euro's volatility affecting European suppliers' profitability. Despite this, strategic acquisitions, like Novartis's expansion into fluorescence imaging, signal optimism. Investors should note that ICG's financial path correlates with global healthcare budgets, which are projected to grow 5% annually through 2030, per World Health Organization data.

Regulatory and Patent Landscape

The regulatory environment shapes ICG's financial trajectory, with patents serving as a bulwark against competition. Core patents, such as those for ICG's chemical synthesis, expired in the U.S. by 2020, triggering a wave of generics that compressed margins by 10-15%. However, secondary patents on delivery systems and combination therapies extend protection until 2027 in key markets, preserving revenue for innovators.

Regulatory bodies like the FDA mandate rigorous testing, with recent guidelines emphasizing biocompatibility for expanded uses. This has delayed some product launches but ensured market credibility. In Europe, the EMA's fast-track approvals for COVID-related shortages in 2021 accelerated ICG supply, demonstrating how adaptive regulations can fuel financial rebounds. Businesses must monitor these shifts, as they directly influence pricing power and market entry barriers.

Challenges and Opportunities

ICG faces headwinds from alternative imaging technologies, such as MRI contrast agents, which compete on accuracy but lag in real-time applications. Supply constraints and raw material costs, exacerbated by global events, could erode profits if not addressed through diversified sourcing. Yet, opportunities abound: the rise of personalized medicine opens doors for ICG in targeted therapies, potentially adding 20% to market value by 2025.

Strategic alliances, like those between pharmaceutical firms and medical device manufacturers, enhance distribution and innovation. For business professionals, investing in ICG-related stocks or partnerships offers high returns, provided they navigate patent risks and regulatory hurdles effectively.

Conclusion

In summary, Indocyanine Green's market dynamics reflect a balance of growth drivers and competitive pressures, while its financial trajectory points to sustained profitability amid evolving healthcare demands. By leveraging technological advancements and regulatory insights, stakeholders can capitalize on this drug's potential in an increasingly precise medical landscape.

Key Takeaways

  • ICG's market is growing at a 7.5% CAGR, driven by demand in minimally invasive surgeries and imaging.
  • Revenues are projected to reach $220 million by 2028, supported by R&D in new applications.
  • Patent expirations pose risks, but regulatory approvals create opportunities for expansion.
  • North America dominates, but Asia-Pacific offers the fastest growth potential.
  • Financial stability depends on managing supply chains and competition from generics.

FAQs

What factors are driving the growth of the ICG market?

The ICG market is expanding due to increased adoption in fluorescence-guided surgeries and rising prevalence of chronic diseases, with a projected CAGR of 7.5% through 2030.

How do patent expirations affect ICG's financial performance?

Patent expirations have introduced generics, reducing prices by up to 30% and compressing margins, but secondary patents provide temporary protection for key manufacturers.

What are the main competitors to ICG in medical imaging?

ICG competes with agents like fluorescein sodium, but its real-time fluorescence capabilities give it an advantage in surgical applications.

How might global economic conditions impact ICG's revenue?

Economic downturns could delay elective procedures, potentially slowing revenue growth, though long-term healthcare investments may mitigate these effects.

What investment opportunities exist in the ICG sector?

Investors can target companies like Akorn or Novartis for high ROI in R&D-driven expansions, focusing on emerging markets for untapped growth.

Sources

  1. Grand View Research. "Indocyanine Green Market Size, Share & Trends Analysis Report by Application (Ophthalmology, Cardiology), by Region, and Segment Forecasts, 2023-2030." Accessed via company report summary.
  2. World Health Organization. "Global Spending on Health: A World View." 2023 edition, used for healthcare budget projections.
  3. Akorn Pharmaceuticals. "Annual Financial Report 2023," referenced for revenue and earnings data.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.